Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Species distribution and antifungal susceptibility of invasive Candida isolates from Canadian hospitals: results of the CANWARD 2011-16 study.

Fuller J, Dingle TC, Bull A, Shokoples S, Laverdière M, Baxter MR, Adam HJ, Karlowsky JA, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv48-iv54. doi: 10.1093/jac/dkz287.

PMID:
31505645
2.

Measuring the involvement in family life of children with autism spectrum disorder: A DBPNet study.

Schwartz J, Huntington N, Toomey M, Laverdiere M, Bevans K, Blum N, Bridgemohan C.

Res Dev Disabil. 2018 Dec;83:18-27. doi: 10.1016/j.ridd.2018.07.012. Epub 2018 Aug 6.

PMID:
30092382
3.

Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: A single-center study in Québec, Canada.

Lavallée C, Labbé AC, Talbot JD, Alonso CD, Marr KA, Cohen S, Laverdière M, Dufresne SF.

Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12648. Epub 2017 Jan 11.

PMID:
27943498
4.

Preliminary Validation of the PROMIS Parent-Proxy Peer Relationships Measure in Children with Autism Spectrum Disorder: A DBPNet Study.

Toomey M, Schwartz J, Laverdiere M, Tucker CA, Bevans K, Forrest CB, Blum NJ.

J Dev Behav Pediatr. 2016 Nov/Dec;37(9):724-729.

PMID:
27801722
5.

High frequency of pathogenic Aspergillus species among nonsporulating moulds from respiratory tract samples.

Dufresne PJ, Moonjely SS, Ozaki K, Tremblay C, Laverdière M, Dufresne SF.

Med Mycol. 2017 Feb 1;55(2):233-236. doi: 10.1093/mmy/myw064. Epub 2016 Aug 23.

PMID:
27555561
6.

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.

Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jiménez JL, Candoni A, Raad I, Laverdiere M, Langston A, Kartsonis N, Van Iersel M, Connelly N, Waskin H.

J Antimicrob Chemother. 2016 Jun;71(6):1747. doi: 10.1093/jac/dkw079. Epub 2016 Mar 8. No abstract available.

PMID:
26960721
7.

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.

Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jiménez JL, Candoni A, Raad I, Laverdiere M, Langston A, Kartsonis N, Van Iersel M, Connelly N, Waskin H.

J Antimicrob Chemother. 2016 Mar;71(3):718-26. doi: 10.1093/jac/dkv380. Epub 2015 Nov 26. Erratum in: J Antimicrob Chemother. 2016 Jun;71(6):1747.

8.

Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.

Neofytos D, Ostrander D, Shoham S, Laverdiere M, Hiemenz J, Nguyen H, Clarke W, Brass L, Lu N, Marr KA.

Transpl Infect Dis. 2015 Dec;17(6):831-7. doi: 10.1111/tid.12454. Epub 2015 Nov 25.

9.

Guidance on the use of antiviral drugs for influenza in acute care facilities in Canada, 2014-2015.

Stiver HG, Evans GA, Aoki FY, Allen UD, Laverdière M.

Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):e5-8.

10.

Guidance for practitioners on the use of antiviral drugs to control influenza outbreaks in long-term care facilities in Canada, 2014-2015 season.

Aoki FY, Allen UD, Stiver HG, Laverdière M, Skowronski D, Evans GA.

Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):e1-4.

11.

Correction for dufresne et Al., instability of Aspergillus galactomannan in stored clinical samples.

Dufresne SF, Beauchemin S, Lavallée C, Laverdière M.

J Clin Microbiol. 2015 Feb;53(2):756. doi: 10.1128/JCM.03369-14. No abstract available.

12.

Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective.

Laverdiere M, Bow EJ, Rotstein C, Autmizguine J, Broady R, Garber G, Haider S, Hussaini T, Husain S, Ovetchkine P, Seki JT, Théorêt Y.

Can J Infect Dis Med Microbiol. 2014 Nov-Dec;25(6):327-43. Review.

13.

Instability of Aspergillus galactomannan in stored clinical samples.

Dufresne SF, Beauchemin S, Lavallée C, Laverdière M.

J Clin Microbiol. 2014 Dec;52(12):4435-6. doi: 10.1128/JCM.01912-14. Epub 2014 Sep 24. No abstract available. Erratum in: J Clin Microbiol. 2015 Feb;53(2):756.

14.

Incidence of invasive aspergillosis following remission-induction chemotherapy for acute leukemia: a retrospective cohort study in a single Canadian tertiary care centre.

Barkati S, Dufresne SF, Bélanger S, Vadnais B, Bergeron J, Labbé AC, Laverdière M.

CMAJ Open. 2014 May 7;2(2):E86-93. doi: 10.9778/cmajo.20130062. eCollection 2014 Apr.

15.

Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

Duarte RF, López-Jiménez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, Chandrasekar P, Langston A, Perfect J, Ma L, van Iersel ML, Connelly N, Kartsonis N, Waskin H.

Antimicrob Agents Chemother. 2014 Oct;58(10):5758-65. doi: 10.1128/AAC.03050-14. Epub 2014 Jul 21.

16.

The Prospective Antifungal Therapy Alliance(®) registry: A two-centre Canadian experience.

Haider S, Rotstein C, Horn D, Laverdiere M, Azie N.

Can J Infect Dis Med Microbiol. 2014 Spring;25(1):17-23.

17.

Why Candida sepsis should matter to ICU physicians.

Skrobik Y, Laverdiere M.

Crit Care Clin. 2013 Oct;29(4):853-64. doi: 10.1016/j.ccc.2013.06.007. Epub 2013 Aug 20. Review.

PMID:
24094381
18.

Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors.

Alonso CD, Dufresne SF, Hanna DB, Labbé AC, Treadway SB, Neofytos D, Bélanger S, Huff CA, Laverdière M, Marr KA.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1502-8. doi: 10.1016/j.bbmt.2013.07.022. Epub 2013 Aug 1.

19.

Treatment of invasive candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials.

Kanji JN, Laverdière M, Rotstein C, Walsh TJ, Shah PS, Haider S.

Leuk Lymphoma. 2013 Jul;54(7):1479-87. doi: 10.3109/10428194.2012.745073. Epub 2012 Dec 3. Review.

PMID:
23113686
20.

Translational control through eIF2alpha phosphorylation during the Leishmania differentiation process.

Cloutier S, Laverdière M, Chou MN, Boilard N, Chow C, Papadopoulou B.

PLoS One. 2012;7(5):e35085. doi: 10.1371/journal.pone.0035085. Epub 2012 May 31.

21.

A case of Japanese encephalitis virus infection acquired during a trip in Thailand.

Langevin S, Libman M, Drebot MA, Laverdière M.

J Travel Med. 2012 Mar-Apr;19(2):127-9. doi: 10.1111/j.1708-8305.2011.00582.x. Epub 2012 Feb 28.

22.

Ten-year experience with fungal peritonitis in peritoneal dialysis patients: antifungal susceptibility patterns in a North-American center.

Levallois J, Nadeau-Fredette AC, Labbé AC, Laverdière M, Ouimet D, Vallée M.

Int J Infect Dis. 2012 Jan;16(1):e41-3. doi: 10.1016/j.ijid.2011.09.016. Epub 2011 Nov 4. Review.

23.

Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis.

Campoli P, Al Abdallah Q, Robitaille R, Solis NV, Fielhaber JA, Kristof AS, Laverdiere M, Filler SG, Sheppard DC.

Antimicrob Agents Chemother. 2011 Dec;55(12):5732-9. doi: 10.1128/AAC.00637-11. Epub 2011 Sep 19.

24.

Sporadic Legionnaires' disease: the role of domestic electric hot-water tanks.

Dufresne SF, Locas MC, Duchesne A, Restieri C, Ismaïl J, Lefebvre B, Labbé AC, Dion R, Plante M, Laverdière M.

Epidemiol Infect. 2012 Jan;140(1):172-81. doi: 10.1017/S0950268811000355. Epub 2011 Mar 14.

PMID:
21396146
25.

Serum β-d-glucan of critically ill patients with suspected ventilator-associated pneumonia: preliminary observations.

Heyland D, Jiang X, Day AG, Laverdiere M.

J Crit Care. 2011 Oct;26(5):536.e1-536.e9. doi: 10.1016/j.jcrc.2011.01.002. Epub 2011 Mar 3.

PMID:
21376516
26.

In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.

Walkty A, Adam HJ, Laverdière M, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):348-55. doi: 10.1016/j.diagmicrobio.2010.10.032.

PMID:
21353964
27.

High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.

Su SH, Martel-Laferrière V, Labbé AC, Snydman DR, Kent D, Laverdière M, Béliveau C, Logvinenko T, Cohen S, Lachance S, Kiss T, Roy J.

Biol Blood Marrow Transplant. 2011 Jul;17(7):1012-7. doi: 10.1016/j.bbmt.2010.10.025. Epub 2010 Oct 25.

28.

Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies.

Luong ML, Filion C, Labbé AC, Roy J, Pépin J, Cadrin-Tourigny J, Carignan S, Sheppard DC, Laverdière M.

Diagn Microbiol Infect Dis. 2010 Oct;68(2):132-9. doi: 10.1016/j.diagmicrobio.2010.03.017.

PMID:
20846585
29.

A single-centre 10-year experience with Candida bloodstream infections.

Labbé AC, Pépin J, Patiño C, Castonguay S, Restieri C, Laverdiere M.

Can J Infect Dis Med Microbiol. 2009 Summer;20(2):45-50.

30.

Pediatric antifungal therapy. Part II: neonatal infections.

Allen U, Richardson S, McGuire W, Bow E, Robinson J, Rotstein C, Doyle J, Davies D, Hui C, Le Saux N, Merchant P, Laverdiere M, Read S.

Minerva Pediatr. 2010 Feb;62(1):71-8. Review.

PMID:
20212400
31.

Pediatric antifungal therapy. Part I: focus on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and invasive candidiasis in immunocompromised pediatric patients.

Allen U, Bow E, Doyle J, Richardson S, Robinson J, Rotstein C, Davies D, Hui C, Le Saux N, Laverdiere M, Read S.

Minerva Pediatr. 2010 Feb;62(1):57-69. Review.

PMID:
20212399
32.

Retrospective evaluation of caspofungin therapy in invasive aspergillosis (RECAM-IA).

Wisniewski T, Klimko N, Laverdiere M, Kiertiburanakul S, Kliasova G, Trenschel R, Kumar RN.

Mycoses. 2011 Jul;54(4):e148-53. doi: 10.1111/j.1439-0507.2010.01861.x. Epub 2010 Feb 24.

PMID:
20202110
33.

Canadian clinical practice guidelines for invasive candidiasis in adults.

Bow EJ, Evans G, Fuller J, Laverdière M, Rotstein C, Rennie R, Shafran SD, Sheppard D, Carle S, Phillips P, Vinh DC.

Can J Infect Dis Med Microbiol. 2010 Winter;21(4):e122-50.

34.

Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW.

Emerg Infect Dis. 2009 Jul;15(7):1068-76. doi: 10.3201/eid1507.090043.

35.

Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults.

Rotstein C, Cragin L, Laverdière M, Garber G, Bow EJ, Scalera A, Roberts C, Sorenson SV.

Can J Infect Dis Med Microbiol. 2008 May;19(3):219-26.

36.

Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005.

St-Germain G, Laverdière M, Pelletier R, René P, Bourgault AM, Lemieux C, Libman M.

Can J Infect Dis Med Microbiol. 2008 Jan;19(1):55-62.

37.

Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis.

Kontoyiannis DP, Ratanatharathorn V, Young JA, Raymond J, Laverdière M, Denning DW, Patterson TF, Facklam D, Kovanda L, Arnold L, Lau W, Buell D, Marr KA.

Transpl Infect Dis. 2009 Feb;11(1):89-93. doi: 10.1111/j.1399-3062.2008.00349.x. Epub 2008 Oct 8.

PMID:
18983417
38.

Utility of the germ tube test for direct identification of Candida albicans from positive blood culture bottles.

Sheppard DC, Locas MC, Restieri C, Laverdiere M.

J Clin Microbiol. 2008 Oct;46(10):3508-9. doi: 10.1128/JCM.01113-08. Epub 2008 Aug 6.

39.

Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.

Labbé AC, Poirier L, Maccannell D, Louie T, Savoie M, Béliveau C, Laverdière M, Pépin J.

Antimicrob Agents Chemother. 2008 Sep;52(9):3180-7. doi: 10.1128/AAC.00146-08. Epub 2008 Jun 23.

40.

Hemangiomatosis in two sets of premature twins.

Laverdiere M, Aggarawal R, Blei F.

Am J Perinatol. 2008 May;25(5):295-300. doi: 10.1055/s-2008-1076604. Epub 2008 Apr 24.

PMID:
18437643
41.

An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada.

Rotstein C, Laverdière M, Marciniak A, Ali F.

Can J Infect Dis Med Microbiol. 2004 Sep;15(5):277-84.

42.

High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.

Labbé AC, Su SH, Laverdière M, Pépin J, Patiño C, Cohen S, Kiss T, Lachance S, Sauvageau G, Busque L, Roy DC, Roy J.

Biol Blood Marrow Transplant. 2007 Oct;13(10):1192-200. Epub 2007 Aug 3.

43.

Susceptibility patterns of Candida species recovered from Canadian intensive care units.

Laverdiere M, Labbé AC, Restieri C, Rotstein C, Heyland D, Madger S, Stewart T.

J Crit Care. 2007 Sep;22(3):245-50. Epub 2007 Jan 31.

PMID:
17869976
44.

Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain.

Lamontagne F, Labbé AC, Haeck O, Lesur O, Lalancette M, Patino C, Leblanc M, Laverdière M, Pépin J.

Ann Surg. 2007 Feb;245(2):267-72.

45.

Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.

Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, Chandrasekar PH, Cleary JD, Cordonnier C, Cornely OA, Cuenca-Estrella M, Daly JS, Daoura N, Denning DW, dePauw B, de Repentigny L, Dignani MC, Dismukes WE, Donnelly JP, Donowitz GR, Dupont B, Drusano G, Ellis M, Espinel-Ingroff A, Fishman JA, Fleming R, Forrest G, Ghannoum M, Goldman M, Grazziutti M, Greene JN, Greenberg RN, Gubbins PO, Hadley S, Herbrecht R, Hiemenz JW, Hope W, Hospenthal DR, Husain S, Ito JI, Jacobson RM, Johnson M, Keating MR, Kett DH, Knapp K, Kontoyiannis DP, Krcmery VC, Larsen R, Laverdiere M, Ljungman P, Lortholary O, Maertens J, Marriott D, Mattiuzzi G, McGinnis MR, Morris M, Nucci M, Odds FC, Pankey GA, Patterson T, Pfaller M, Razonable RR, Reboli AC, Rinaldi MG, Roberts GD, Rodriguez Tudela JL, Rotstein C, Ruhnke M, Schuster M, Shoham S, Sia IG, Siebel N, Silviera F, Singh N, Sobel J, Solomkin JS, Sorrell TC, Steinbach WJ, Temesgen Z, Tortorano A, Vartivarian S, VerWeij P, Viscoli C, Viviani MA, Walker RC, Wheat JL, Wiley J, Williamson P, Wingard JR, Yu VL, Zaoutis T.

Clin Infect Dis. 2006 Oct 15;43(8):1031-9. Epub 2006 Sep 13. No abstract available. Erratum in: Clin Infect Dis. 2007 Mar 15;44(6):894.

PMID:
16983616
46.

Prenatal culture-based screening of Streptococcus agalactiae colonisation: resistance against erythromycin and clindamycin.

Lavergne V, Laverdière M, Duchesne A, Béliveau C, Delorme J, Di Zazzo A, Labbé AC.

Eur J Clin Microbiol Infect Dis. 2006 Aug;25(8):532-4. No abstract available.

PMID:
16874484
47.

A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.

Bow EJ, Rotstein C, Noskin GA, Laverdiere M, Schwarer AP, Segal BH, Seymour JF, Szer J, Sanche S.

Clin Infect Dis. 2006 Aug 15;43(4):447-59. Epub 2006 Jul 10.

PMID:
16838234
48.

What is the clinical significance of infusing hematopoietic cell grafts contaminated with bacteria?

Kelly M, Roy DC, Labbe AC, Laverdiere M.

Bone Marrow Transplant. 2006 Aug;38(3):183-8. Epub 2006 Jun 19.

PMID:
16785868
49.

Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada.

MacCannell DR, Louie TJ, Gregson DB, Laverdiere M, Labbe AC, Laing F, Henwick S.

J Clin Microbiol. 2006 Jun;44(6):2147-52.

50.

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS.

J Antimicrob Chemother. 2006 Apr;57(4):705-8. Epub 2006 Feb 7.

PMID:
16464893

Supplemental Content

Loading ...
Support Center